CYBN

Cybin

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 2

Sell signal 1

consensus rating "Strong Buy"

ample liquidity

EPS Below Expectations

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About CYBN

Cybin Inc.

A biopharmaceutical company that developing psychedelic therapeutics for psychiatric disorders

Industry

Pharmaceutical

Established Date

Invalid Date

Listing Date

08/05/2021

Exchange

American Stock Exchange

Full-time Employees

Fiscal Year Ends

03-31

Website

www.cybin.com

Security Type

Common stock

Office address

100 King Street West, Suite 5600, Toronto, Ontario, Canada M5X 1C9

Business

Introduction

Cybin Inc., was founded in 2019 in Ontario, Canada. The company operates in Canada, the United States, the United Kingdom and Ireland. The company focuses on developing psychedelics into therapies by designing patented drug discovery platforms, innovative drug delivery systems, novel formulation methods and treatment options for mental health disorders.

Company Financials

EPS

CYBN has released its 2025 Q1 earnings. EPS was reported at -0.01, versus the expected -0.03, beating expectations. The chart below visualizes how CYBN has performed over recent quarters, highlighting trends in earnings surprises.